The Journal of Nuclear Medicine ahead-of-print tip sheet: July 23, 2026

Reston, VA (July 23, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

Summaries of the newly published research articles are provided below.

Dual-Energy SPECT May Enable Faster Monitoring of ¹⁷⁷Lu-PSMA Therapy
A study evaluated whether dual-energy 360° CZT total-body SPECT/CT could shorten imaging time after ¹⁷⁷Lu-PSMA therapy. In 20 patients with prostate cancer, researchers compared 9-minute and 18-minute dual-energy scans with an 18-minute single-energy protocol, assessing tumor volume and SUVmean against PSMA PET.

PSMA PET-Based Model Helps Predict Outcomes After ¹⁷⁷Lu-PSMA Therapy
Researchers evaluated a previously developed prognostic model in 174 patients with metastatic castration-resistant prostate cancer who underwent ¹⁸F-flotufolastat PET before ¹⁷⁷Lu-PSMA I&T therapy. The model was assessed for its ability to predict overall survival, PSA progression-free survival, and PSA response, with patients stratified into low- and high-risk groups.

Timing Between PSMA PET and Therapy May Affect Assessment of Prostate Cancer
A study of 87 patients with treatment-resistant prostate cancer examined whether disease progression occurred between baseline PSMA PET and the start of ¹⁷⁷Lu-PSMA-617 therapy. Interim progression was observed in more than one-third of patients and was associated with a longer interval between baseline imaging and treatment initiation.

Visit the JNM website for the latest research and follow our Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 90 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.